Review
Biotechnology & Applied Microbiology
Piotr Eder, Aleksandra Zielinska, Jacek Karczewski, Agnieszka Dobrowolska, Ryszard Slomski, Eliana B. Souto
Summary: Despite significant advancements in the treatment of inflammatory bowel disease in recent years, there is still a large room for improvement. Oral anti-TNF-alpha antibody therapy is hypothesized to provide targeted anti-inflammatory effects without significant systemic exposure, potentially improving long-term treatment outcomes and safety. Various attempts have been made to design oral formulations of these molecules, aiming to enter a new era of treatment for IBD.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Review
Medicine, General & Internal
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll, Jon Florholmen
Summary: This review discusses the use of TNF antibodies in treating IBD and the evaluation of therapeutic efficacy using current and novel biomarkers. It emphasizes the urgent need for validation and comparison studies of promising novel biomarkers to improve their value in clinical practice.
Article
Medicine, General & Internal
Suraj Sakaram, Yehudit Hasin-Brumshtein, Purvesh Khatri, Yudong D. He, Timothy E. Sweeney
Summary: The study identified a robust gene signature for predicting the response of IBD patients to anti-TNF-alpha treatment prior to initiation. These seven genes can effectively distinguish between responders and non-responders to anti-TNF-alpha, showing high sensitivity, specificity, and accuracy in predicting patient responsiveness.
Article
Medicine, General & Internal
Giorgia Colombo, Gian Paolo Caviglia, Alberto Ravera, Elisa Tribocco, Simone Frara, Chiara Rosso, Cristina Travelli, Armando A. Genazzani, Davide Giuseppe Ribaldone
Summary: This study investigated the levels of eNAMPT and eNAPRT in the serum and stools of IBD patients and found that both factors were significantly increased in IBD patients and correlated with disease severity and inflammatory markers. Furthermore, serum NAMPT levels were associated with treatment failure in patients starting adalimumab therapy. Therefore, a prospective clinical trial evaluating the relationship between eNAMPT and eNAPRT levels and response to biologics in IBD patients is recommended.
FRONTIERS IN MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Maria Jose Casanova, Maria Chaparro, Oscar Nantes, Jose Manuel Benitez, Maria Rojas-Feria, Jesus Castro-Poceiro, Jose Maria Huguet, Albert Martin-Cardona, Marta Aicart-Ramos, Joan Tosca, Maria del Mar Martin-Rodriguez, Carlos Gonzalez-Munoza, Miriam Manosa, Eduardo Leo-Carnerero, Luis Javier Lamuela-Calvo, Isabel Perez-Martinez, Luis Bujanda, Joaquin Hinojosa, Ramon Pajares, Federico Arguelles-Arias, Jose Lazaro Perez-Calle, Gloria Esther Rodriguez-Gonzalez, Jordi Guardiola, Manuel Barreiro-de Acosta, Javier P. Gisbert
Summary: After discontinuation of anti-TNF therapy, a significant proportion of patients remained in remission, and retreatment with the same anti-TNF was effective in case of relapse.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Gastroenterology & Hepatology
Matheus Freitas Cardoso de Azevedo, Luisa Leite Barros, Filipe Fernandes Justus, Jane Oba, Karoline Soares Garcia, Camilla de Almeida Martins, Alexandre de Sousa Carlos, Andre Zonetti Arruda Leite, Aytan Miranda Sipahi, Natalia Sousa Freitas Queiroz, Aderson Omar Mourao Cintra Damiao
Summary: This study aimed to identify risk factors for active tuberculosis (TB) development in inflammatory bowel disease (IBD) patients and describe their clinical characteristics and outcomes in a tertiary referral center in Brazil. Results showed that active TB was significantly associated with IBD diagnosis older than 17 years and anti-TNF therapy. Reintroduction of anti-TNFs after TB treatment appears to be safe.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Tung On Yau, Jayakumar Vadakekolathu, Gemma Ann Foulds, Guodong Du, Benjamin Dickins, Christos Polytarchou, Sergio Rutella
Summary: This study collected transcriptomic data from inflammatory bowel disease patients receiving anti-TNF-alpha therapy and found that hyperactive neutrophil chemotaxis influenced the response to anti-TNF-alpha treatment. IL13RA2 was identified as a potential biomarker to predict the response to anti-TNF-alpha treatment.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Nikolaos-Panagiotis Andreou, Maria Gazouli, Ioannis E. Koutroubakis
Summary: This study investigated the association of serum antinuclear antibodies (ANA) with infliximab (IFX) and adalimumab (ADA) trough levels (TLs) and anti-drug antibodies in patients with inflammatory bowel disease (IBD) receiving IFX or ADA therapy. The results showed that ANA positivity was associated with lower TLs in IBD patients receiving anti-TNF therapy, but no significant association was found with the development of cutaneous or rheumatological manifestations.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Article
Gastroenterology & Hepatology
Shiv Gandhi, Sara Zelman, Ricardo Eduardo De Armas, Christopher Hemond, Alexander N. Levy, Siddharth Singh, Joshua Korzenik, Sushrut Jangi
Summary: Patients with both MS and IBD had similar rates of stricturing, fistulizing, and extensive IBD compared to IBD controls. Although MS-IBD patients were less likely to start anti-TNF therapy, their risk of surgery did not worsen during follow-up.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Medicine, General & Internal
Marcin Sochal, Jakub Fichna, Agata Gabryelska, Renata Talar-Wojnarowska, Piotr Bialasiewicz, Ewa Malecka-Wojciesko
Summary: This study evaluated serum levels of chemerin in patients with inflammatory bowel disease (IBD), finding that chemerin levels were significantly higher during exacerbation of the disease and correlated with severity of Crohn's disease (CD). Anti-TNF therapy significantly decreased chemerin levels, suggesting its potential relationship with disease activity in IBD and potential clinical utility as a monitoring tool.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Summary: Stringent latent tuberculosis (LTB) screening and chemoprophylaxis can significantly reduce the risk of tuberculosis (TB) reactivation in patients receiving anti-tumor necrosis factor (anti-TNF) therapy, especially in TB endemic regions.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Multidisciplinary Sciences
Takahiro Amano, Shinichiro Shinzaki, Akiko Asakura, Taku Tashiro, Mizuki Tani, Yuriko Otake, Takeo Yoshihara, Shuko Iwatani, Takuya Yamada, Yuko Sakakibara, Naoto Osugi, Shuji Ishii, Satoshi Egawa, Manabu Araki, Yuki Arimoto, Masanori Nakahara, Yoko Murayama, Ichizo Kobayashi, Kazuo Kinoshita, Hiroyuki Ogawa, Satoshi Hiyama, Narihiro Shibukawa, Masato Komori, Yorihide Okuda, Takashi Kizu, Shunsuke Yoshii, Yoshiki Tsujii, Yoshito Hayashi, Takahiro Inoue, Hideki Iijima, Tetsuo Takehara
Summary: This study evaluated the efficacy and safety of anti-tumor necrosis factor treatment for elderly onset inflammatory bowel disease patients. The results showed that after 52 weeks of treatment, elderly onset patients had lower clinical and steroid-free remission rates compared to non-elderly patients, and a higher rate of cumulative severe adverse events.
SCIENTIFIC REPORTS
(2022)
Article
Immunology
Hadar Edelman-Klapper, Keren Masha Rabinowitz, Eran Zittan, Ariella Bar-Gil Shitrit, Idan Goren, Irit Avni-Biron, Jacob E. Ollech, Lev Lichtenstein, Hagar Banai-Eran, Henit Yanai, Yifat Snir, Maor H. Pauker, Adi Friedenberg, Adva Levy-Barda, Yelena Broitman, Haim Ben Zvi, Tsachi-Tsadok Perets, Rami Eliakim, Revital Barkan, Sophy Goren, Dani Cohen, Iris Dotan
Summary: Vaccination plays a crucial role in controlling the COVID-19 pandemic, but patients with inflammatory bowel diseases (IBDs) treated with anti-TNF-alpha may have lower serologic response after a third vaccine dose. This study suggests that a fourth vaccine dose may be needed for this patient population.
Article
Gastroenterology & Hepatology
Manasi Agrawal, Elizabeth A. Spencer, Jean-Frederic Colombel, Ryan C. Ungaro
Summary: Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic, progressive, immune-mediated diseases of adults and children with no cure. Delay in diagnosis is common and associated with adverse outcomes, highlighting the importance of early diagnosis and prompt treatment. Risk stratification based on clinical, demographic, and serologic markers can guide selection of first-line therapy in personalized medicine.
Article
Food Science & Technology
Van-Long Truong, Woo-Sik Jeong
Summary: Polyphenols, including phenolic acids, flavonoids, and procyanidins, are abundant in food and beverage derived from plants. Tea polyphenols have established antioxidant and anti-inflammatory properties, and their supplementation can prevent inflammatory conditions and improve the outcome of patients with inflammatory bowel diseases (IBD).
FOOD SCIENCE AND HUMAN WELLNESS
(2022)
